(Q34656044)

English

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial (English)

1 reference

Europe PubMed Central

3 August 2017

phase III clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David Cunningham

1

object named as

David Cunningham

1 reference

Europe PubMed Central

3 August 2017

author name string

Istvan Lang

2

1 reference

Europe PubMed Central

3 August 2017

Eugenio Marcuello

3

1 reference

Europe PubMed Central

3 August 2017

Vito Lorusso

4

1 reference

Europe PubMed Central

3 August 2017

Janja Ocvirk

5

1 reference

Europe PubMed Central

3 August 2017

Dong Bok Shin

6

1 reference

Europe PubMed Central

3 August 2017

Derek Jonker

7

1 reference

Europe PubMed Central

3 August 2017

Stuart Osborne

8

1 reference

Europe PubMed Central

3 August 2017

Niko Andre

9

1 reference

Europe PubMed Central

3 August 2017

Daniel Waterkamp

10

1 reference

Europe PubMed Central

3 August 2017

Mark P Saunders

11

1 reference

Europe PubMed Central

3 August 2017

AVEX study investigators

12

1 reference

Europe PubMed Central

3 August 2017

publication date

10 September 2013

1 reference

Europe PubMed Central

3 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

3 August 2017

14

1 reference

Europe PubMed Central

3 August 2017

11

1 reference

Europe PubMed Central

3 August 2017

1077-1085

1 reference

Europe PubMed Central

3 August 2017

Physiologic aspects of aging: impact on cancer management and decision making, part II.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Physiologic aspects of aging: impact on cancer management and decision making, part I.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for the elderly patient with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970154-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70154-2

1 reference

Europe PubMed Central

3 August 2017

release_yslhykdfo5ahvopwhissufnyku

1 reference

https://api.fatcat.wiki/v0/release/yslhykdfo5ahvopwhissufnyku

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34656044&oldid=1971868293"